证券代码：000590 证券简称：启迪药业 公告编号：2023-051 一、审议通过《2023 年第三季度报告》 审核意见如下：经审核，监事会认为董事会编制和审议公司 2023 年第三季 度报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票赞成，0 票反对，0 票弃权 特此公告。 启迪药业集团股份公司 启迪药业集团股份公司 第十届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 启迪药业集团股份公司（以下简称"公司"）第十届监事会第三次会议通知 于 2023 年 10 月 16 日通过电子邮件的方式发出，会议于 2023 年 10 月 26 日以通 讯表决方式召开。会议应参加表决监事 3 人，实参加表决监事 3 人。符合有关法 律、法规、规章和公司章程的规定。会议审议如下事项： 监事会 2023 年 10 月 28 日 ...

证券代码：000590 证券简称：启迪药业 公告编号：2023-053 启迪药业集团股份公司 关于全资子公司投资建设原药材仓库项目的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 公司住所：湖南省衡阳市雁峰区罗金桥1号（雁峰区工业项目集聚区） 法定代表人：文戈 重要内容提示： 投资标的名称：古汉中药有限公司原药材仓库项目 投资金额：1,500万元人民币 一、对外投资概述 启迪药业集团股份公司（以下简称"公司"）于 2023 年 10 月 26 日召开的十届董 事会第三次会议审议通过了《关于全资子公司投资建设原药材仓库项目的议案》，同意 公司全资子公司古汉中药有限公司（以下简称"古汉中药"）投资建设原药材仓库项目， 预计投资总额为 1,500 万元。 本次项目投资无需提交股东大会审议批准，本次项目投资不属于关联交易和重大 资产重组事项。 二、对外投资主体基本情况 公司名称：古汉中药有限公司 成立日期：2007年1月18日 注册资本：13,500.00万元 统一社会信用代码：9143040079688025XK 经营范围：药品生产；药品委托生产；食品生产；保 ...

启迪药业集团股份公司 股东大会议事规则 1、总则 1.1 为了规范启迪药业集团股份公司（以下简称"公司"）股东大会及其参会者的行 为，明确股东大会的职责权限，保证公司股东大会依法行使职权，根据《中华人民共和国公 司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上 市公司股东大会规则》和本公司《公司章程》的规定，制定本规则。 1.2 公司应当严格按照法律、行政法规、本规则及《公司章程》的相关规定召开股东 大会，保证股东能够依法行使权利。董事会应当切实履行职责，认真、按时组织股东大会。 公司全体董事应当勤勉尽责，确保股东大会正常召开和依法行使职权。 1.4 股东大会分为年度股东大会和临时股东大会。年度股东大会每年召开一次，应当 于上一会计年度结束后的六个月内举行。临时股东大会不定期召开，出现以下情形时，公司 在事实发生之日起两个月内召开临时股东大会。 1.4.1 董事人数不足《公司法》规定的法定最低人数，或者少于《公司章程》所定人 数的三分之二时； 1.4.2 公司未弥补的亏损达实收股本总额的三分之一时； 1.4.3 单独或者合并持有公司百分之十以上股份的股东（以下简称"提议股东" ...

启迪药业集团股份公司 独立董事工作制度 1、 总 则 1.1 为进一步完善启迪药业集团股份公司（下称"公司"或"本公司"）的治理结 构，促进公司的规范运作，维护公司整体利益，保障全体股东特别是中小股东大合法权 益不受损害，根据《公司法》《证券法》《上市公司独立董事管理办法》（以下简称为"《独 董办法》"）《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引 第 1 号-规范运作》等相关法律法规以及《公司章程》的有关规定，结合公司的实际情 况制定本制度。 1.2 公司独立董事是指不在本公司担任除董事外的其他职务，并与本公司及其主 要股东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独立客观判 断的关系的董事。独立董事应独立履行职责，不受公司主要股东、实际控制人以及其他 与本公司存在利害关系的单位或个人的影响。 1.3 独立董事对公司及全体股东负有诚信与勤勉的义务，独立董事应按照相关法律、 行政法规、中国证券监督管理委员会规定、证券交易所业务规则和《公司章程》的要求， 认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用，维护公司整体利 益，保护中小股东合法权益。 1.4 独立 ...

启迪药业集团股份公司 董事会战略委员会实施细则 1. 总 则 1.1 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规划，健全投资 决策程序，加强决策科学性，提高重大投资决策的效益和决策的质量，完善公司治理结构， 根据《中华人民共和国公司法》、《中华人民共和国证券法》《上市公司治理准则》《公 司章程》及其他有关规定，公司特设立董事会战略委员会，并制定本实施细则。 1.2 董事会战略委员会是董事会设立的专门工作机构，主要负责对公司长期发展战略 和重大投资决策进行研究并提出建议。 2. 人员组成 2.1 战略委员会成员由三至五名董事组成。 2.2 战略委员会委员由董事长、二分之一以上独立董事或者全体董事的三分之一以上 提名，并由董事会选举产生。 2.3 战略委员会设主任一名，由公司董事长担任，负责主持委员会工作。 2.4 战略委员会任期与董事会任期一致，委员任期届满，连选可以连任。期间如有委 员不再担任公司董事职务，自动失去委员资格，并由委员会根据上述第2.1条至第2.3条规 定补足委员人数。 2.5 战略委员会可以根据工作需要成立相应的工作机构。 3. 职责权限 3.1 战略委员会的主要职责权限： 3 ...

Financial Performance - The company's operating revenue for 2022 was CNY 350,528,110.13, representing a 16.54% increase compared to CNY 300,774,612.76 in 2021[23]. - The net profit attributable to shareholders decreased by 48.80% to CNY 18,145,855.14 from CNY 35,438,603.68 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 11,599,403.81, down 48.10% from CNY 22,350,567.85 in 2021[23]. - Basic earnings per share decreased by 48.78% to CNY 0.0758 from CNY 0.1480 in the previous year[23]. - The total assets at the end of 2022 were CNY 1,166,753,854.92, a 20.55% increase from CNY 967,825,750.64 at the end of 2021[23]. - The weighted average return on net assets was 2.63%, down from 5.35% in 2021, reflecting a decrease of 2.72%[23]. - The company reported a total revenue of ¥113.98 million in Q4 2022, with a total annual revenue of ¥350.53 million[27]. - The company achieved operating revenue of ¥350,528,110.13, a year-on-year increase of 16.54%[44]. - Net profit attributable to shareholders decreased by 48.80% to ¥18,145,855.14, primarily due to rising raw material costs and increased marketing expenses[44]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 116.20% to CNY 54,473,687.13 from CNY 25,196,296.92 in 2021[23]. - The company experienced significant cash flow fluctuations, with a net cash flow from operating activities of -¥38.06 million in Q1 and ¥44.83 million in Q4[27]. - The net cash flow from financing activities surged to ¥111,520,200.47, primarily due to increased bank borrowings[63]. - The total investment during the reporting period was ¥283,796,257.20, a significant increase of 475.07% compared to the previous year[69]. - The company has invested a total of RMB 191,186,559.01 in projects using raised funds as of December 31, 2022[80]. Acquisitions and Market Expansion - The company acquired 90% of Qidi Bio for ¥23.5 million to enhance its health product trade business[45]. - In August 2022, the company purchased 100% of Guangdong Xiantong Pharmaceutical for ¥220 million to expand its product line and market competitiveness[45]. - The company plans to expand its market presence by entering three new regions in 2023, aiming for a 15% increase in market share[110]. - The company will focus on its core business and expand its market presence nationwide, leveraging the acquisition of Guangdong Xiantong to enhance its terminal sales network and accelerate market expansion[90]. Research and Development - The company is focusing on digital transformation and enhancing its information management through the "Ancient Han Chinese Medicine Smart Factory" initiative[43]. - The company is increasing R&D investment, focusing on traditional Chinese medicine and health products, and establishing an innovative R&D platform to enhance clinical value research and product development[92]. - R&D expenses rose by 58.07% to ¥13,103,555.45, reflecting increased investment in research and development[59]. - The number of R&D personnel increased by 30.91% to 72, with a notable rise in the proportion of staff under 30 years old[61]. Governance and Compliance - The company has established a robust governance structure, complying with relevant laws and regulations, ensuring effective decision-making and supervision[99]. - The company maintains a complete and independent business system, ensuring no reliance on the controlling shareholder for operations[100]. - The financial management system is independent, with separate bank accounts and tax registrations, ensuring no interference from the controlling shareholder[103]. - The company has not reported any significant differences in governance practices compared to regulatory requirements[99]. Environmental Responsibility - The company operates a wastewater treatment system with a capacity of 1000m³/d, achieving a removal efficiency of 98% for pollutants[147]. - The company has established a comprehensive emergency response plan for sudden environmental incidents, which was revised in June 2022[155]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[155]. - The company adheres to multiple environmental protection laws and standards, including the "Comprehensive Emission Standard for Air Pollutants"[143]. Challenges and Risks - The company has faced challenges due to intensified competition in the pharmaceutical sector, influenced by policies such as medical insurance cost control and volume-based procurement[35]. - The company faces risks related to product structure dependence, particularly on the "Guhang Yangshengjing" series, and aims to diversify its product line to mitigate these risks[93]. - The company is exposed to raw material price fluctuations, particularly for traditional Chinese medicine materials, and will implement strategic procurement and cost management measures to control expenses[94]. - The company’s subsidiary, Hengyang Pharmaceutical, is currently facing losses due to outdated product structures and will focus on adjusting its product mix and improving profitability[96]. Social Responsibility - In 2022, the company invested CNY 30,000 in rural revitalization efforts, establishing sales channels for local specialty agricultural products[156]. - The company donated a total value of over CNY 360,000 in health products, including 151 boxes of Gu Han health essence and 4,993 packages of Gan Jiang drink[156]. Shareholder Information - The total number of shares after the recent changes is 239,471,267, with 99.96% being unrestricted shares[195]. - The largest shareholder, Qidi Technology Service Limited, holds 29.41% of the shares, totaling 70,432,904 shares[197]. - The company has not issued any new shares or made any changes to the share structure during the reporting period[196]. - The total number of shareholders at the end of the reporting period is 25,900[197].

Financial Performance - The company's operating revenue for the first half of 2023 was ¥190,050,700.64, representing a 22.35% increase compared to ¥155,329,759.94 in the same period last year[24]. - The net profit attributable to shareholders decreased by 44.76% to ¥6,382,540.84 from ¥11,554,184.55 year-on-year[24]. - Basic earnings per share fell by 44.61% to ¥0.0267 from ¥0.0482 in the same period last year[24]. - The company reported a decrease of 28.95% in net profit after deducting non-recurring gains and losses, amounting to ¥3,549,187.89 compared to ¥4,995,227.47 last year[24]. - The weighted average return on net assets decreased to 0.91% from 1.68% year-on-year[24]. - The company reported a total investment of 195.87 million yuan for the annual production of 400 million bottles of Gu Han Yang Sheng oral liquid, with 100 million yuan funded by raised capital[64]. - The company reported a net loss improved to CNY -54,583,126.10 from CNY -60,965,666.94, indicating a reduction in losses[129]. - The company's net profit for the first half of 2023 was reported at 45.89 million yuan, compared to a loss of 116.9 million yuan in the same period last year, indicating a turnaround in profitability[158]. Cash Flow and Investments - The net cash flow from operating activities turned negative at -¥40,029,572.99, a decline of 190.65% compared to ¥44,160,594.59 in the previous year[24]. - The company's cash flow from operating activities showed a net outflow of ¥40,029,572.99, a decrease of 190.65% compared to the previous year[44]. - The net cash flow from investment activities was 17,511,220.15 yuan, a decrease of 28.3% from 24,400,626.06 yuan in the first half of 2022[143]. - The net cash flow from financing activities was -13,883,512.64 yuan, compared to a positive cash flow of 1,142,827.80 yuan in the same period of 2022[143]. - The total cash and cash equivalents at the end of the period were 198,411,359.21 yuan, down 37.2% from 316,065,329.07 yuan at the end of the first half of 2022[143]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,124,199,451.52, down 3.65% from ¥1,166,753,854.92 at the end of the previous year[24]. - The total liabilities decreased to CNY 415,432,073.81 from CNY 464,259,983.71, indicating a reduction of 10.5%[129]. - The company's total equity increased to CNY 708,767,377.71 from CNY 702,493,871.21, reflecting a growth of 0.4%[129]. - The company's accounts receivable amounted to RMB 79,912,406.66 at the end of the reporting period, reflecting a change in collection efficiency[51]. - The total number of shares outstanding is 239,471,267, with 99.96% being unrestricted shares[112]. Research and Development - Research and development investment rose by 14.31% to ¥6,093,258.48, reflecting the company's commitment to innovation[44]. - The company is advancing its research and development efforts, including the approval of national standards for its key products and the establishment of a digital transformation initiative to enhance operational efficiency[37]. - Research and development expenditures have increased by 5.7% compared to the previous period, indicating a focus on innovation[152]. Market and Sales Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on traditional Chinese and Western medicine, with a strong brand presence and product variety, making it one of the major pharmaceutical enterprises in Hunan Province[32]. - The company has implemented a dual sales model, utilizing both agency distribution and direct supply to enhance market reach and control over product flow, particularly for medical insurance products[34]. - In the first half of the year, the company optimized its sales structure and enhanced brand promotion, resulting in improved market share and sales performance through innovative marketing strategies[35]. - The company aims to leverage its unique advantages in traditional Chinese medicine to capitalize on the growing health awareness among consumers, driven by demographic changes and economic development[32]. - The company is actively exploring new growth opportunities through e-commerce and expanding its product line to meet diverse consumer needs[35]. Environmental Compliance - The environmental protection license for the traditional Chinese medicine company is valid from May 28, 2023, to May 27, 2028[83]. - The company has reported that it complies with various environmental standards, including the "Comprehensive Emission Standard of Air Pollutants" and "Water Pollutants Discharge Standard for Pharmaceutical Industry"[83]. - The company achieved a wastewater treatment efficiency of 98% and a waste gas pollutant removal efficiency of 90% with its environmental facilities[85]. Shareholder Information - The annual shareholders' meeting had a participation rate of 46.27% on May 18, 2023[77]. - The company plans not to distribute cash dividends or issue bonus shares for the first half of 2023[79]. - The largest shareholder, Tsinghua Technology Service Limited, holds 29.41% of shares, totaling 70,432,904 shares, which are frozen[114]. Risk Management - The company has outlined potential risks and countermeasures in its management discussion section, which investors are encouraged to review[4]. - The company faces risks related to product structure concentration, with a high dependency on the "Gu Han Yang Sheng Jing" series[72]. - The company is implementing measures to control raw material price fluctuations, including strategic procurement and inventory management[73]. Corporate Governance - The financial report was approved by the board of directors on August 23, 2023[163]. - The financial statements are prepared based on the accounting standards issued by the Ministry of Finance, reflecting the company's financial position as of June 30, 2023[168]. - The company has not reported any significant changes in its debt levels, maintaining a consistent financial leverage ratio[152].

证券代码：000590 证券简称：启迪药业 公告编号：2023-045 启迪药业集团股份公司 启迪药业集团股份公司（以下简称"公司"）第十届监事会第二次会议通知 于 2023 年 8 月 11 日通过电子邮件的方式发出，会议于 2023 年 8 月 21 日以现场 结合通讯表决方式召开。会议应参加表决监事 3 人，实参加表决监事 3 人，其中 以通讯方式表决 1 人，无委托出席情况。符合有关法律、法规、规章和公司章程 的规定。会议审议如下事项： 一、审议通过《2023 年半年度报告》全文及摘要 审核意见如下：经审核，监事会认为董事会编制和审议公司 2023 年半年度 报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完 整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票赞成，0 票反对，0 票弃权 二、审议通过《2023 年半年度募集资金存放和使用情况的专项报告》 表决结果：3票赞成，0票反对，0票弃权。 第十届董事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 审核意见如下：经审核 ...

法定代表人：焦祺森 主管会计工作的负责人：唐婷 会计机构负责人：朱倩 汇总表第 1 页 2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：启迪药业集团股份公司 单位：万元 | | | 占用方与上 | 上市公司核 | 年期初占 2023 | 年 2023 | 月占用 1-6 | | 年 2023 1-6 | 月 | 年 2023 1-6 | | 2023 年6 | 月 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | 用资金余额 | | 累计发生金额（不 | | 占用资金的利 | | 月偿还累计 | | 30 号占用 | | 原因 | 占用性质 | | | | 联关系 | 目 | | | 含利息） | | 息(如有) | | 发生金额 | | 资金余额 | | | | | 控股股东、实际控 | | | | | | | | | | | | | ...

启迪药业集团股份公司 2023 年半年度募集资金存放和使用情况报告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：000590 证券简称：启迪药业 公告编号：2023-047 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证监会《关于核准启迪古汉集团股份有限公司非公开发行股票的批 复》（证监许可[2017]87 号）文件的核准，公司获准非公开发行不超过 1,614 万股新股。本次实际发行人民币普通股（A 股）16,140,000 股，发行价格为人民 币 17.76 元/股，募集资金总额为人民币 286,646,400.00 元，扣除发行费用后的 募集资金净额为人民币 278,696,400.00 元。 本次募集资金到账时间为 2017 年 5 月 2 日，募集资金到位情况已经天职国 际会计师事务所（特殊普通合伙）审验，并于 2017 年 5 月 3 日出具天职业字 [2017]12468 号验资报告。 （二）以前年度已使用金额、本年度使用金额及当前余额 截至 2023 年 6 月 30 日，公司累计使用募集资金人民币 200,93 ...